INVO Bioscience (IVOB)

KEY FIGURES (Latest Twelve Months - LTM)
Yesterday's Close 0.43 $
PE Ratio - LTM 0.0
Market Capitalisation 35.3 mil
Latest Shares Outstanding 83.1 mil
Earnings pS (EPS) $
Dividend pS (DPS) 0.00 ¢
Dividend Yield 0.0 %
Dividend Payout Ratio %
Revenue per Employee 22,549 $
Effective Tax Rate 0.0 %
Float 42.2 mil
Float as % of Shares Outstanding 0.5 %
Foreign Sales mil
Domestic Sales mil
Selling, General & Adm/tive (SG&A) as % of Revenue 0.00 %
Research & Devlopment (R&D) as % of Revenue 0.00 %
Gross Profit Margin 0.0 %
EBITDA Margin 0.0 %
Pre-Tax Profit Margin 0.0 %
Assets Turnover 0.0 %
Return on Assets (ROA) 0.0 %
Return on Equity (ROE) 0.0 %
Return on Capital Invested (ROCI) 0.0 %
Current Ratio
Leverage Ratio (Assets/Equity)
Interest Cover
Total Debt/Equity (Gearing Ratio)
LT Debt/Total Capital 0.0 %
Working Capital pS 0.00 $
Cash pS 0.00 $
Book-Value pS -0.04 $
Tangible Book-Value pS 0.00 $
Cash Flow pS 0.00 $
Free Cash Flow pS $

KEY FIGURES (LTM): Price info
Price/Book Ratio -0.57
Price/Tangible Book Ratio 0.00
Price/Cash Flow -33.9
Price/Free Cash Flow
P/E as % of Industry Group 1.0 %
P/E as % of Sector Segment 0.0 %

They haven't filed lately. They are operating on a shoe-string budget until FDA approval. As a result, however, they have been able to stay afloat without dilution or external financing, the directors not taking a salary for years.

Email from Director:

Good morning Mike,


First off please call me Rob, Robert is too formal! I do not understand why people are anxious, whenever anything of significance has happened we update the shareholders. We outlined exactly what is going on and we are not the twitter and facebook types that feel the need to let everyone know what is going on every minute. We have continued to do everything we can without any compensation and barley covering our out of pocket expenses over the years to walk away now. We believe in the INVOcell and that it will have a significant impact in the market, assisting many more couples in having children they cannot have now. We also have an allegiance to our long term investors and believers. Those that have been with us for a long time know what we have endured and they continue to stick with us. We have no control or influence over any shareholder who is buying or selling and do not know who has been doing all the buying and selling over the past year bsp;

Thank you for your support and looking out for the Company and what others think.


Back to today's question - Yes you may but let me edit it a bit, as we already submitted our response back to the FDA. Please post

Thank you for your inquiry. As we outlined in our last shareholder update on our website, we are working with the FDA responding to any and all questions as quickly as they come in. It is a process that we believe is still moving forward, as a matter of fact we received some comments in this morning that we have already responded too.

We were completely up to date in providing the FDA with responses to all of their inquiries. Gaining FDA acceptance is our number one priority.

All we know is that our submission is in process by their review team and they will get back to us when they are ready. It is not an issue that we can force as they hold all the cards.

Hopefully it will be in the near future but as we have experienced in the past everything is on their timetable as they have a lot on their plate.

I know I did not give you a definitive answer but I do not have one. You now know what we know, which is the same as we have stated to all, just a slightly more current version. Believe me we will let everyone know when something of substance happens.

Thank you for your investment in INVO Bioscience.

Have a good weekend,


Rob

Robert J. Bowdring
Director
INVO Bioscience Inc.
Office/Fax - 978-878-9505 ext.508
www.INVOBioscience.com